MX2017010873A - Composiciones y métodos para el tratamiento de "placas y ovillos" en humanos y animales. - Google Patents

Composiciones y métodos para el tratamiento de "placas y ovillos" en humanos y animales.

Info

Publication number
MX2017010873A
MX2017010873A MX2017010873A MX2017010873A MX2017010873A MX 2017010873 A MX2017010873 A MX 2017010873A MX 2017010873 A MX2017010873 A MX 2017010873A MX 2017010873 A MX2017010873 A MX 2017010873A MX 2017010873 A MX2017010873 A MX 2017010873A
Authority
MX
Mexico
Prior art keywords
tangles
plaques
methods
humans
animals
Prior art date
Application number
MX2017010873A
Other languages
English (en)
Inventor
Cummings Joel
Hu Qubai
D Snow Alan
Lake Thomas
Cam Judy
Original Assignee
Cognitive Clarity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognitive Clarity Inc filed Critical Cognitive Clarity Inc
Publication of MX2017010873A publication Critical patent/MX2017010873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones y métodos para tratar "placas" y "ovillos" cerebrales en un paciente o un animal, en el que el método comprende la administración de una cantidad terapéuticamente eficaz de una composición que comprende un extracto de Uncaria tomentosa y un extracto de té Oolong.
MX2017010873A 2015-02-27 2016-02-25 Composiciones y métodos para el tratamiento de "placas y ovillos" en humanos y animales. MX2017010873A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126026P 2015-02-27 2015-02-27
US201562170822P 2015-06-04 2015-06-04
PCT/US2016/019572 WO2016138270A2 (en) 2015-02-27 2016-02-25 Compositions and methods for the treatment of "plaques and tangles" in humans and animals

Publications (1)

Publication Number Publication Date
MX2017010873A true MX2017010873A (es) 2018-11-12

Family

ID=56789214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010873A MX2017010873A (es) 2015-02-27 2016-02-25 Composiciones y métodos para el tratamiento de "placas y ovillos" en humanos y animales.

Country Status (10)

Country Link
US (3) US10307454B2 (es)
EP (1) EP3261655A4 (es)
JP (1) JP6796072B2 (es)
CN (1) CN107530389B (es)
AU (1) AU2016222650B2 (es)
CA (1) CA3015127C (es)
HK (1) HK1247845A1 (es)
MX (1) MX2017010873A (es)
SG (1) SG11201706861QA (es)
WO (1) WO2016138270A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6796072B2 (ja) 2015-02-27 2020-12-02 コグニティヴ クラリティ インコーポレイテッド ヒトおよび動物における「プラークおよびもつれ」の処置のための組成物と方法
JP2022512372A (ja) 2018-12-12 2022-02-03 コグニティヴ クラリティ インコーポレイテッド ヒトおよび動物における「プラークおよびタングル」の処置のための組成物および方法
US11883457B1 (en) 2022-09-06 2024-01-30 Optigenex Inc. Method of enhancing cognition in individuals with at least normal cognition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683698A (en) 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
US6346280B1 (en) * 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
EP1019044B1 (en) * 1997-05-15 2007-04-11 University of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
US6264994B1 (en) 1997-05-15 2001-07-24 University Of Washington Compositions for treating alzheimer's disease and other amyloidoses
CA2323090C (en) 1998-03-13 2009-08-04 University Of Washington In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases
JP2003171298A (ja) * 2001-12-11 2003-06-17 Nonogawa Shoji Kk 抗アレルギー剤
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1679060A1 (en) 2003-10-09 2006-07-12 Advangen, Inc. Hair growth stimulant composition
JP4321769B2 (ja) * 2004-04-13 2009-08-26 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 抗ヒスタミン用組成物、アレルギ性鼻炎の予防および治療用組成物、花粉症の予防および治療用組成物およびじんま疹治療用組成物
JP4954552B2 (ja) * 2006-01-07 2012-06-20 日本メナード化粧品株式会社 抗アレルギー剤
JP2007230977A (ja) * 2006-03-03 2007-09-13 Naris Cosmetics Co Ltd 顆粒球・マクロファージコロニー刺激因子（ｇｍ−ｃｓｆ）産生抑制剤ｉｉ
JP2007277163A (ja) 2006-04-06 2007-10-25 Uha Mikakuto Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤
TW200812637A (en) * 2006-09-15 2008-03-16 jun-er Wang Vegetable composition for cleaning oral cavity
JP2010013423A (ja) 2008-07-07 2010-01-21 Lion Corp ジペプチジルペプチダーゼ−ｉｖ阻害剤
JP5688606B2 (ja) 2012-02-17 2015-03-25 株式会社シェフコ 機能性原料を含有する水素含有飲料の製造方法
JP6796072B2 (ja) 2015-02-27 2020-12-02 コグニティヴ クラリティ インコーポレイテッド ヒトおよび動物における「プラークおよびもつれ」の処置のための組成物と方法

Also Published As

Publication number Publication date
WO2016138270A3 (en) 2016-10-27
CN107530389A (zh) 2018-01-02
CA3015127C (en) 2023-10-10
JP2018513838A (ja) 2018-05-31
EP3261655A4 (en) 2018-10-10
US20190350996A1 (en) 2019-11-21
US20170333512A1 (en) 2017-11-23
WO2016138270A2 (en) 2016-09-01
US10350258B2 (en) 2019-07-16
HK1247845A1 (zh) 2018-10-05
US20160250273A1 (en) 2016-09-01
EP3261655A2 (en) 2018-01-03
AU2016222650A1 (en) 2017-09-07
CN107530389B (zh) 2021-10-26
US11376300B2 (en) 2022-07-05
AU2016222650B2 (en) 2021-11-04
CA3015127A1 (en) 2016-09-01
SG11201706861QA (en) 2017-09-28
US20190240279A9 (en) 2019-08-08
JP6796072B2 (ja) 2020-12-02
US10307454B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021015234A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
ZA201908241B (en) N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2017011937A (es) Antagonistas del receptor de nk-3 para el tratamiento terapeutico o cosmetico de la grasa corporal excesiva.
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
PL3199171T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania degeneracyjnym zaburzeniom neurologicznym, zawierająca, jako składnik aktywny, mieszaninę ekstraktu z kory korzenia piwonii drzewiastej, korzenia dzięgielu dahuryjskiego i korzenia przewiercienia lub ich frakcję
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
MX2017010873A (es) Composiciones y métodos para el tratamiento de "placas y ovillos" en humanos y animales.
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2014116015A3 (ko) 자죽염을 포함하는 알츠하이머병 예방용 조성물 및 자죽염의 제조방법
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
PH12021551342A1 (en) Compositions and methods for the treatment of "plaques and tangles" in humans and animals
GB2550750A (en) Anthelmintic compounds
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EP3795170C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE